Barclays sets CHRS target value at $46 ($1.8 Billion valuation) and MNTA target value at $22 ($1.5 Billion valuation). So, he gives almost no credit for MNTA's biosimilar platform.
http://www.theflyonthewall.com/permalinks/entry.php?symbol=chrs Coherus Biosciences initiated with an Overweight at Barclays Barclays analyst Douglas Tsao started Coherus Biosciences with an Overweight rating saying the company's exclusive focus on biosimilars should allow it to "navigate the patent landscape nimbly" and meet the "high bar" for U.S. approval with label extrapolation. The analyst put a $46 price target on the stock.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.